Rheumatoid Arthritis Market to Experience Notable Growth in Forecast Span by 2036, DelveInsight Predicts

Rheumatoid Arthritis Market to Experience Notable Growth in Forecast Span by 2036, DelveInsight Predicts https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav https://www.delveinsight.com/consulting The Rheumatoid Arthritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Rheumatoid Arthritis pipeline products will significantly revolutionize the Rheumatoid Arthritis market dynamics.DelveInsight's "Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Rheumatoid Arthritis, historical and forecasted epidemiology as well as the Rheumatoid Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.The Rheumatoid Arthritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2022 to 2036. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.To Know in detail about the Rheumatoid Arthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Rheumatoid Arthritis Market InsightSome of the key facts of the Rheumatoid Arthritis Market Report:• The rheumatoid arthritis market size was estimated at approximately USD 31,000 million in 2025 and is anticipated to expand at a modest CAGR of 2% during the 2026-2036 forecast period.• In July 2026, Precision immunology company Scipher Medicine announced its merger with Chemomab Therapeutics, following the identification of the Israeli biotech's liver disease candidate as a strong strategic fit with Scipher's expertise. The combined company will continue operating under the Scipher name while utilizing Chemomab's Nasdaq listing, with the stock ticker changing to "SCIP." The merged entity will primarily focus on advancing nebokitug, Chemomab's anti-CCL24 antibody, which is slated to enter a Phase II clinical trial for the treatment of rheumatoid arthritis.• In July 2026, Emerging and investigational therapies for rheumatoid arthritis are expanding the treatment landscape, with Janus kinase (JAK) inhibitors and Bruton's tyrosine kinase (BTK) inhibitors showing significant potential to reduce inflammation and improve disease management. In addition, innovative approaches such as vagus nerve stimulation are under investigation as potential therapies to enhance clinical outcomes and improve patients' quality of life.• In June 2026, Generic drug manufacturer Aurobindo Pharma has secured final approval from the U.S. Food and Drug Administration (FDA) for its Tofacitinib Tablets USP, available in 5 mg and 10 mg strengths. The approved product has been confirmed as bioequivalent and therapeutically equivalent to Xeljanz Tablets (5 mg and 10 mg), marketed by PF Prism C.V. Manufacturing will take place at APL Healthcare's Unit IV, a subsidiary of Aurobindo Pharma, with commercial launch planned immediately following the approval.• In June 2026, According to the latest guidance from the European Alliance of Associations for Rheumatology (EULAR), the increasing availability of biosimilar disease-modifying antirheumatic drugs (DMARDs) and the introduction of generic Janus kinase inhibitors (JAK inhibitors) have significantly influenced recommendations on treatment sequencing for patients with rheumatoid arthritis (RA). Published in the Annals of the Rheumatic Diseases, the 2025 EULAR recommendations for managing RA with synthetic and biologic DMARDs represent the most streamlined version of the guidance so far, reducing the number of recommendations from 11 to 9. The update was undertaken three years after the 2022 revision to incorporate new evidence from strategic clinical trials and emerging safety data related to JAK inhibitors, prompting a reevaluation of the current therapeutic approach.• In January 2026, SetPoint Medical, a biotechnology company focused on innovative treatments for chronic autoimmune conditions, announced the publication of results from its RESET-RA study in Nature Medicine. This pivotal, double-blind, randomized, sham-controlled trial assessed the safety and effectiveness of the SetPoint System, an implantable neuroimmune modulation device that targets the vagus nerve. The therapy is designed for adults with moderate to severe rheumatoid arthritis (RA) who have an inadequate response to, or are unable to tolerate, currently available advanced RA treatments, including biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs).• In September 2025, Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for children aged six years and older weighing at least 40 kg with moderate to severe plaque psoriasis (PsO) who are eligible for systemic therapy or phototherapy, as well as for active psoriatic arthritis (PsA). This approval marks TREMFYA® as the first and only IL-23 inhibitor authorized for these pediatric indications, expanding upon its prior FDA approvals for adults with moderate to severe plaque PsO in 2017 and active PsA in 2022.• In April 2025, The European Medicines Agency (EMA) granted approval for Cullinan Therapeutics' clinical trial application of CLN-978, a potential treatment for rheumatoid arthritis (RA). This Phase I open-label study will enroll patients with active, treatment-resistant RA, as defined by the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria. The trial is designed to evaluate the drug's pharmacokinetics, pharmacodynamics, safety profile, and its effect on disease activity.• In February 2025, AnaptysBio's Phase IIb trial evaluating rosinilimab for rheumatoid arthritis (RA) has delivered promising results, with some patients achieving the highest recorded response rates by week 14. Remarkably, 69% of participants attained low disease activity. The U.S.-based company presented findings from its randomized RENOIR trial (NCT06041269), which assessed the safety and tolerability of rosinilimab in moderate-to-severe RA patients previously treated with conventional disease-modifying drugs. The study successfully met its primary endpoint, demonstrating a statistically significant improvement in DAS28-CRP scores compared to placebo, reinforcing rosinilimab's potential as an effective RA treatment.• As per Xu et al. (2021), in the US, approximately 1.3 million adults suffer from rheumatoid arthritis, representing 0.6% to 1% of the adult population.• As per Stanciu et al. (2022), the estimated prevalence for rheumatoid arthritis in the adults is around 0.81%, with a higher prevalence for women (1.16%) than for men (0.44%) in the UK.• According to the World Health Organization (2023), about 70% of people living with rheumatoid arthritis are women, and 55% are older than 55 years of age.• As per Jinno et al. (2019) and Bergstra et al. (2018), the targeted therapies usage varies from 18% to 50% in Japan, which is similar to the usage of targeted therapies in the US.• Rheumatoid arthritis mortality has decreased globally over the past three decades. Global age standardized prevalence rate have increased over the same period, and the number of cases is projected to continue to increase.• While rheumatoid arthritis is a systemic autoimmune disease that affects multiple body systems, the joints of hands, wrists, feet, ankles, knees, shoulders and elbows are most often affected.• Key Rheumatoid Arthritis Companies: Abbvie, Eli Lilly and Company/Incyte, Taiho Pharmaceutical, Rise Therapeutics, Cyxone, IGM Biosciences, Regeneron/Sanofi, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others• Key Rheumatoid Arthritis Therapies: Upadacitinib (RINVOQ), Barticinib (OLUMIANT), TAS5315, R-2487, RINVOQ (upadacitinib), Rabeximod (Rob 803), Imvotamab, Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others• The Rheumatoid Arthritis epidemiology based on gender analyzed that according to Pediatric Rheumatology prevalence rate is consistently higher in girls in comparison to boysRheumatoid Arthritis OverviewRheumatoid Arthritis (JIA), also known as juvenile rheumatoid arthritis (JRA), is the most common form of arthritis in children under the age of 16. It is a chronic autoimmune disease characterized by inflammation in the joints, which leads to pain, stiffness, swelling, and sometimes loss of joint function.Get a Free sample for the Rheumatoid Arthritis Market Report:Rheumatoid Arthritis EpidemiologyThe epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.Rheumatoid Arthritis Epidemiology Segmentation:The Rheumatoid Arthritis market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:• Total Prevalent Cases of Rheumatoid Arthritis• Total Diagnosed Prevalent Cases of Rheumatoid Arthritis• Gender-specific Cases of Rheumatoid Arthritis• Age-specific Cases of Rheumatoid Arthritis• Severity-specific Cases of Rheumatoid Arthritis• Patients on Targeted Therapies of Rheumatoid Arthritis• Line-Wise Treated Cases of Rheumatoid ArthritisDownload the report to understand which factors are driving Rheumatoid Arthritis epidemiology trends @ Rheumatoid Arthritis Epidemiological InsightsRheumatoid Arthritis Drugs Uptake and Pipeline Development ActivitiesThe drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Rheumatoid Arthritis market or expected to get launched during the study period. The analysis covers Rheumatoid Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.The report also covers the Rheumatoid Arthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.Rheumatoid Arthritis Therapies and Key Companies• Upadacitinib (RINVOQ): Abbvie• Barticinib (OLUMIANT): Eli Lilly and Company/Incyte• TAS5315: Taiho Pharmaceutical• R-2487: Rise Therapeutics• OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation• RINVOQ (upadacitinib): AbbVie• Rabeximod (Rob 803): Cyxone• Imvotamab: IGM Biosciences• Sarilumab (Kevzara): Regeneron/Sanofi• Baricitinib: Eli Lilly and Company• Certolizumab pegol: UCB BIOSCIENCES GmbH• Upadacitinib: AbbVie• Tofacitinib: Pfizer• Sarilumab SAR153191 (REGN88): Sanofi• GenaKumab: Changchun GeneScience Pharma• AIN457: Novartis• Etanercept: Istituto Giannina GasliniTo know more about Rheumatoid Arthritis treatment, visit @ Rheumatoid Arthritis MedicationsRheumatoid Arthritis Market Drivers• Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Rheumatoid Arthritis• Population rates of social anxiety disorder in children and young people have been investigated in several countries• Many therapies are under investigation in various phases of clinical trialsRheumatoid Arthritis Market Unmet Needs• Challenge in recognition of condition• Development of novel therapies• Limited availability in services• Poor disease understanding• Development of effective treatmentScope of the Rheumatoid Arthritis Market Report• Study Period: 2022-2036• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]• Key Rheumatoid Arthritis Companies: Abbvie, Eli Lilly and Company/Incyte, Taiho Pharmaceutical, Rise Therapeutics, Cyxone, IGM Biosciences, Regeneron/Sanofi, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others• Key Rheumatoid Arthritis Therapies: Upadacitinib (RINVOQ), Barticinib (OLUMIANT), TAS5315, R-2487, RINVOQ (upadacitinib), Rabeximod (Rob 803), Imvotamab, Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others• Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies• Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies• Rheumatoid Arthritis Unmet Needs, KOL's views, Analyst's views, Rheumatoid Arthritis Market Access and ReimbursementMedia ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: info@delveinsight.comCity: AlbanyState: New YorkCountry: United StatesWebsite:About DelveInsightDelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.